Zydus Wellness (531335) Q4 06/07 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 06/07 earnings summary
3 Nov, 2026Executive summary
Sales and other income rose 49% to Rs 438,071 thousand; profit after tax declined 3.65% to Rs 23,897 thousand as advertising spend increased to build brand awareness.
A depreciation-method change added Rs 1,518 thousand to current-year profit, while an Rs 18,820 thousand write-back of prior-year depreciation lifted profit available for appropriation.
Financial highlights
Revenue was Rs 438,071 thousand versus Rs 293,976 thousand; profit before tax was Rs 47,295 thousand versus Rs 47,657 thousand.
Profit after tax was Rs 23,896 thousand versus Rs 24,803 thousand; profit for the year after the depreciation write-back was Rs 42,716 thousand.
Proposed dividend was 10% (Rs 1 per share), totaling Rs 6,522 thousand including dividend tax; Rs 4,500 thousand was transferred to general reserve.
Basic and diluted EPS was Rs 4.29 before extraordinary items and Rs 7.66 after extraordinary items, versus Rs 4.45 in both measures in FY06.
Outlook and guidance
Production capacity expansion was planned to meet increased product demand; management expected initiatives under new ownership to support business growth and improved profitability.
Results of substantial brand-building advertising expenditure were expected to become visible in FY08.
Latest events from Zydus Wellness
- Sales and EBITDA surged as gross margin expanded and brand growth continued.531335
Q2 26/27 - Sales rose, but FY98 ended with a Rs. 78.8 lakh net loss.531335
Q4 97/98 - Revenue rose 42%, profit after tax doubled, and a Rs. 0.60/share dividend was proposed.531335
Q4 02/03 - Sales surged, but FY99 ended with a Rs 45,36,571 loss before tax.531335
Q4 98/99 - Higher sales and production accompanied a narrower loss, but operating cash flow remained negative.531335
Q4 99/00 - FY02 profit improved as new-product investment positioned the business for growth.531335
Q4 01/02 - Sales more than doubled as profits rose and product expansion broadened.531335
Q4 03/04 - Revenue rose 60.75% as capacity expansion and regional growth plans advanced.531335
Q4 04/05 - Sales grew 9.12%, profit held near flat, and Cadila Healthcare took a 61.56% stake.531335
Q4 05/06